Announcements

New Yale Medicine Brand
As you know, on August 31st, Yale Medical Group will rebrand as Yale Medicine, and launch new positioning, 'we care.' As part of this rebranding effort, Yale Cancer Center's name will change to Yale Medicine Cancer Center. All Yale faculty and staff have received additional information on the rebranding efforts from Yale Medical Group leadership. Our website will launch with the new Yale Medicine Cancer Center brand on August 31 and all printed materials will begin updating in September. If you have any questions on the rebranding process for the Cancer Center, please contact Renee Gaudette.

NCI Outstanding Investigator
I am very pleased to announce that Madhav Dhodapkar, MBBS has received an Outstanding Investigator Award from the National Cancer Institute. This prestigious award is given to a distinguished group of accomplished leaders in cancer research each year to support their research efforts. The $7 million grant will support Madhav's research for seven years. His research team will use the funding to combine new approaches for early detection and prevention of cancer, and explore how the immune system regulates the transition to cancer.

Notables

Recent News
Read recent articles featuring experts from Yale Cancer Center
News Center >>

LATEST ARTICLES:
Ranjit Bindra, MD, PhD, a member of our Radiobiology and Radiotherapy Research Program, has received a $50k grant from the Pablove Foundation. The foundation supports research on rare pediatric cancers and will support his work to study "Small Molecule Screening for Novel Rhabdoid Tumor Inhibitors."

Mark Lezenby, MD, a member of our Cancer Prevention and Control Research Program, participated in a Palliative Care Retreat and training at the King Hussein Cancer Center in Amman, Jordan.

Brian Shuch, MD, a member of our Developmental Therapeutics Research Program, has received a Career Development Award (K08) Grant from the National Cancer Institute to support his work to study "Genomic Heterogeneity and the Small Renal Mass."

Yale New Haven Children's Hospital is one of 18 recipients across the country to receive a 2016 Hyundai Impact Grant from Hyundai Hope On Wheels®. The $50,000 Impact Grant was presented to Gary Kupfer, MD, Clinical Program Leader, Pediatric Hematology & Oncology Program at Smilow Cancer Hospital. Yale New Haven Children's Hospital was chosen as a recipient due to its proven track record of caring for children with pediatric cancer. These grant funds will be used to improve care and increase treatment options for children with cancer.

Dr. Roy Herbst, Dr. Patricia LoRusso, and Dr. David Rimm joined a few of our senior fellows at the ASCO/AACR Methods in Clinical Cancer Research Workshop on clinical trial design last week in Vail, CO.
New Member Highlight: Mary Tomayko, MD, PhD

The Cancer Immunology Research Program is happy to welcome Mary Tomayko, MD, PhD, to its membership. Dr. Tomayko, currently an Associate Professor in the Department of Dermatology, has been with Yale since 2001. Her cancer-related work includes diagnosing and treating patients with epithelial cutaneous carcinomas, melanoma, cutaneous lymphoma and patients with adverse reactions to cancer chemotherapy, radiotherapy, and checkpoint blockade. Dr. Tomayko’s lab identified a critical role for PD-1 and its ligands PD-L1 and PD-L2 on the formation of a durable B cell response in mice and has established PD-L2 as one of the best markers for memory B cells in mice. Dr. Tomayko became interested in YCC membership when she and her colleagues began noting an increased risk for the development of bullous pemphigoid, a rare autoantibody-mediated blistering disease, in melanoma and lung cancer patients treated with checkpoint blockade. Her lab is now focused on determining the role of B cells in the immune response to malignancy and on elucidating the consequences that PD-1 inhibition therapy has on the function on regulatory lymphocytes and antibody forming cells.

Research in the News

Genome-editing ‘toolbox’ targets multiple genes at once
A Yale research team has designed a system to modify, or edit, multiple genes in the genome simultaneously, while also minimizing unintended effects. The gene-editing “toolbox” provides a user-friendly solution that scientists can apply to research on cancer and other disciplines, the researchers said.

Radiosurgery and Immunotherapy for Melanoma Patients With Brain Metastases
Read More >>

Genome-editing ‘toolbox’ targets multiple genes at once
Read More >>

Optimal Radium-223 Use Explored as Evolution of mCRPC Care Continues
Read More >>

Join Yale Cancer Center on Facebook
Yale Cancer Center member, Qin Yan, PhD, and his co-authors tackled these challenges in multiple ways. In previous systems, the genome-editing machinery was constantly turned on, leading to more off-target effects. To avoid these effects, the team first developed a strategy to make the machinery "inducible" - able to be turned on and off. They used a drug to turn the machinery on just long enough to edit the genes. This approach allowed them to activate the machinery as needed and for a limited amount of time, reducing off-target effects, they said.

Their gene-editing system also contained a fluorescent marker so the researchers could track whether the editing enzyme was turned on or off in cells, noted Yan.

Funding and Award Opportunities

All current funding opportunities are archived on the Yale Cancer Center website, and searchable by topic, funding agency, and due date. Please check the site often for new opportunities.

Ovarian Cancer Research Program Funding Opportunities for Fiscal Year 2016

The FY16 Defense Appropriations Act provides $20 million (M) to the Department of Defense Ovarian Cancer Research Program (OCRP) to support high-impact ovarian cancer research.

Clinical Development Award

Must be an independent investigator at or above the level of Assistant Professor (or equivalent). Supports the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life.

Application Due: August 10, 2016

Investigator-Initiated Research Award

Must be an independent investigator at or above the level of Assistant Professor (or equivalent). Supports...
meritorious basic and clinically oriented research in ovarian cancer.

**Application Due:** August 10, 2016

Learn More >>

**Ovarian Cancer Academy Award**

Early-Career Investigator must be within the first 3 years of his/her first faculty position (or equivalent) at the time of submission. Supports the addition of new Early-Career Investigators to the unique, interactive virtual academy that will provide intensive mentoring, national networking, and a peer group for junior faculty.

**Application Due:** August 10, 2016

Learn More >>

**Pilot Award**

Investigators at or above the postdoctoral level (or equivalent). Supports innovative, high-risk/high-reward research that could ultimately lead to critical discoveries or major advancements that will drive the field of ovarian cancer research forward.

**Application Due:** August 10, 2016

Learn More >>

**DOD Peer Reviewed Cancer Research Program**

**Funding Opportunities for Fiscal Year 2016**

The FY16 Defense Appropriations Act provides $50 million (M) to the Department of Defense Peer Reviewed Cancer Research Program (PRCRP) to support innovative, high-impact cancer research. The PRCRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications. FY16 PRCRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in April and July 2016. Pre-application and application deadlines will be available when the Program Announcements are released.

**Horizon Award**

PI: A predoctoral candidate within two years of successfully passing qualifying examinations or a postdoctoral fellow within three years of completion of his/her terminal degree (excluding medical residency or family medical leave).

**Application Due:** August 17, 2016

Learn More >>

Here at Smilow Cancer Hospital, we firmly believe that emotional healing contributes signficantly to physical healing. That's why we put maximum effort into every aspect of our patients' care - including the artwork that graces our halls. Patients and families have found solace in our Healing Art Gallery for years, and we're proud to feature "Water Music," a collection of photographs by Roslyn Meyer, PhD, as our next exhibition. Dr. Meyer is a longtime supporter of our hospital's cancer research efforts. We would like to thank her for her continued generosity and hope that her photographs bring moments of peace to all the patients and families who see them.
Yale Cancer Center 2016 Pilot Grants for research in non-AIDS defining cancers in aging HIV+ population

Yale Cancer Center is pleased to announce a Pilot Grant competition for two grants at $120,000 (60,000 annually for two years) for a specific project headed by a member of Yale Cancer Center. The intention of these two grants is to support research in non-AIDS defining cancers in aging HIV+ populations, address cancer disparities in the HIV+ populations of New Haven, foster collaborations and translational activities, encourage junior faculty members to establish their career in this area and have the potential to translate into future independent NIH grant applications.

**Deadline for submission** is 4:00 p.m. on Thursday, August 25. Please direct all questions to Walther Mothes

Learn More >>

SU2C CIRM CLIN 2 Grant Program

Stand Up To Cancer (SU2C) calls upon members of the SU2C community to contribute ideas for clinical research to the California Institute of Regenerative Medicine's (CIRM) CLIN 2 grant program.

In addition to traditional stem cell research, CIRM would like to support projects that involve memory t-cells, progenitor cells (e.g. monocyte-derived dendritic cells), or treatments that target cancer stem cells as their primary mechanism of action.

**Deadline:** Send proposals to proposals@su2c.org by September 2nd. After that date, SU2C and CIRM will review letters of intent on a monthly basis.

Learn More >>

Department of Defense Prostate Cancer Research Program Funding Opportunities for Fiscal Year 2016

The FY16 Defense Appropriations Act provides $80 million (M) to the Department of Defense Prostate Cancer Research Program (PCRP) to support innovative, high-impact prostate cancer research.

**Clinical Consortium Research Site Award**

Independent investigators at or above the level of Assistant Professor (or equivalent). Supports the addition of a Clinical Research Site to the Prostate Cancer Clinical Trials Consortium. Trials that

When Bob Carlson was diagnosed with stage IV lung cancer five years ago, the standard treatments were tough on his body and just didn't work against the disease. That's when he was told a clinical trial might be an option, and he visited Smilow Cancer Hospital. Now, a few years into his trial, Bob is feeling much better than he ever did during his standard treatments, and can still pursue things he loves, like photography. "A clinical trial gave me a chance to be alive," Bob said. "If it didn't work, I knew it would be helping future generations, so it was a win win in my mind."

Drs. David Rimm and Roy Herbst are busy attending this year's AACR/ASCO Workshop on Methods in Clinical Cancer Research in Vail, Colorado, but not too busy for a quick bike ride. They are training for the upcoming Closer to Free Ride - Smilow Cancer Hospital's largest annual fundraiser. We're incredibly proud to have a team of healthcare providers who truly care about their patients.
incorporate investigations of biomarkers for risk assessment, early detection, prediction of aggressiveness, and/or progression of prostate cancer are encouraged.

**Pre-Application Due:** September 15, 2016
[Learn More >>](#)

Susan G. Komen 2016/2017 GRADUATE TRAINING IN DISPARITIES RESEARCH (GTDR) Grants

GTDR Grants are intended to establish and/or to sustain a training program for graduate students who are seeking careers dedicated to understanding and eliminating disparities in breast cancer outcomes across population groups.

**Application Due:** September 2016
[Learn More>>](#)

Department of Defense Breast Cancer Research Program Funding Opportunities for Fiscal Year 2016 (FY16)

The Fiscal Year 2016 (FY16) Defense Appropriations Act provides $120 million (M) to the Department of Defense Breast Cancer Research Program (BCRP) to support innovative, high-impact breast cancer research to accelerate progress toward ending breast cancer.

FY16 BCRP Program Announcements and General Application Instructions for the following award mechanism is posted on the Grants.gov website. Breakthrough Award Funding Levels 1 and 2 will be available in late August.

**Breakthrough Award**

**Funding Levels 1 and 2:**

- Investigators at all academic levels (or equivalent)
- Postdoctoral fellows are eligible and encouraged to apply
[Learn More >>](#)

**Funding Levels 3 and 4:**

- Independent investigators at all academic levels (or equivalent)
- Supports promising research that has the potential to lead to or make breakthroughs in breast cancer.

[Read More >>](#)
• Potential impact of the research may be near-term or long-term, but it must be significant and go beyond an incremental advancement.

• Pre-Application Submission Deadline: September 14, 2016

Learn More >>

Melanoma Research Alliance Grants
The Melanoma Research Alliance (MRA) is pleased to announce a Request for Proposals (RFP) for high-impact translational research that has the potential to lead to near-term clinical application in melanoma prevention, detection, diagnosis, staging, and treatment. This cycle, proposals will be accepted for Young Investigator Awards, Established Investigator Awards, Pilot Awards, and Academic-Industry Partnership Awards. Application Deadline: October 21, 2016

Learn More >>

Recent Publications

Emerging biological therapies for the treatment of myelodysplastic syndromes.

Read More >>

Regression of chemotherapy-resistant Polymerase epsilon (POLE) ultra-mutated and MSH6 hyper-mutated endometrial tumors with nivolumab.

Read More >>


Read More >>

Join us at the @connecticutopen and help support #breastcancer care at #Smilow Cancer Hospital

Custom #Cancer Treatment From Your #Genes from @WebMD featuring @YaleCancer’s sequencing lab w/ Dr. Richard Lifton http://wb.md/2auV7Mi

Team Live Positive and @YNHH nurse Maureen Raucci prepare for @CTFRide @NBCConnecticut http://bit.ly/2agY1x9

Could you be at risk for #headandneck #cancer? #WHNCD http://bit.do/ceC5C

Proud to have Dr. Sidi Chen awarded a @StBaldricks grant for #childhoodcancer research to study brain tumors #btsm

@DrRoyHerbstYale & Dr. Rimm getting ready for @CTFRide on September 10! Join us -Connecticut’s most inspiring ride!

Dr. Kupfer accepts #ImpactGrant from Hyundai @hopeonwheels to support #pediatriccancer @YNHH #endchildhoodcancer

Phase I Unit opens @YaleCancer to care for patients on early therapeutic #clinicaltrials http://bit.ly/2a6kOoN

Smilow Cancer Hospital's Screening and Cancer Prevention program at the Community Fun Day #earlydetection #NHV

Special thanks to our Lion Hearts-celebrating 10 years of making a difference in #breastcancer research and care.

Closer to Free
Proposing prognostic thresholds for lymph node yield in clinically lymph node-negative and lymph node-positive cancers of the oral cavity.
Read More >>

The role of minimally invasive interval debulking surgery in advanced epithelial ovarian cancer.
Read More >>

Evolving Immunotherapy Approaches for Renal Cell Carcinoma.
Read More >>

Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer.
Read More >>

PD-1 axis inhibitors in EGFR and ALK Driven Lung Cancer: Lost cause?
Read More >>

Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia.
Read More >>

MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.
Read More >>

Submissions
Please submit your recent publication and grant announcements to:

Renee Gaudette
Director, Public Affairs and Marketing
renee.gaudette@yale.edu
Malignant Melanoma: Beyond the Basics.
Read More >>